How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Publication|Articles|October 23, 2023
- October 2023
- Volume 89
- Issue 10
Pharmacists Pet Peeves: October 2023
Advertisement
You Snooze, You Lose
When the prescription was waiting for pickup for 14 days so we return it to stock, but the patient gets mad that they have to wait 20 minutes for us to refill it again.
Articles in this issue
about 3 years ago
Interactive Case Studies: October 2023about 3 years ago
Condition State Management: Stroke Watchabout 3 years ago
Celebrate Pharmacists Who Are Trailblazers in MTMabout 3 years ago
Weight Loss: OTC Case Studiesabout 3 years ago
Counsel Patients, Parents on the HPV Vaccineabout 3 years ago
Generic Product News: October 2023about 3 years ago
RX Product News: October 2023about 3 years ago
The Medical Marijuana and Cannabidiol Research Expansion ActAdvertisement
Related to this article
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Garlic has a long history in traditional medicine, but evidence for its benefits varies by preparation, and patients taking medications that increase bleeding risk should use it with caution.
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
Advertisement
Advertisement
Trending on Pharmacy Times
1
From Recognition to Prior Authorization: ATTR-CM Diagnosis Gaps
2
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
3
FDA Approves Perioperative Durvalumab Plus Enfortumab Vedotin-ejfv for MIBC
4
Glucose Monitoring: Timing Makes Every Reading Count
5